FORMULATIONS INHIBITING SARS-CoV-2 VIRUS
AssigneeAnkh Life Sciences Limited
InventorsGene H. Zaid, Beth Ann Wolf, Robert Preston Moore, Larry D. Crow, Jason H. West
Life of this patent
Estimating the term…
Abstract
The treatment of human subjects exposed to, or potentially exposed to SARS-CoV-2 virus, or suffering from COVID-19, comprises the step of administering to the human subjects a formulation comprising turmeric, Peganum harmala, and Arum palaestinum, and/or variants thereof. Methods of inhibiting SARS-CoV-2 viral replication are also described.
Claims12
A method of inhibiting viral replication in a human subject exposed to or at risk of exposure to SARS-CoV-2 virus, or suffering from COVID-19, comprising the step of administering to the subject a prophylactically or therapeutically effective amount of a formulation comprising a synergistic blend of turmeric, Peganum harmala, and Arum palaestinum, and/or the relevant isomers, tautomers, enantiomers, esters, derivatives, metal complexes, prodrugs, solvates, metabolites, and pharmaceutically acceptable salts of the foregoing, which said formulation inhibits replication of said SARS-CoV-2 virus in said subject.
A pharmaceutical formulation comprising a synergistic blend of turmeric, Peganum harmala, and Arum palaestinum, and/or the relevant isomers, tautomers, enantiomers, esters, derivatives, metal complexes, prodrugs, solvates, metabolites, and pharmaceutically acceptable salts of the foregoing, for inhibiting replication of SARS-CoV-2 virus in a subject or for the treatment of a human subject suffering from COVID-19.
A method of inhibiting SARS-CoV-2 viral replication, comprising the step of contacting said virus with a formulation comprising turmeric, Peganum harmala, and Arum palaestinum, and/or relevant the isomers, tautomers, enantiomers, esters, derivatives, metal complexes, prodrugs, solvates, metabolites, and pharmaceutically acceptable salts of the foregoing.
Dependencies are inferred from the claim text.